back to top
HomeMarket£2,000 invested in penny share Angle simply 3 months in the past...

£2,000 invested in penny share Angle simply 3 months in the past would now be value…

-

Picture supply: Getty Photographs

A penny share referred to as Angle (LSE: AGL) has roared again to life on the backside of my portfolio. I bear in mind it did this on the similar time final yr, earlier than slumping beneath a £50m market-cap. Have to be a new-year optimism factor.

As I write, it’s priced at 16.4p, which is 111% larger than firstly of November. This implies a plucky investor who put two grand into this penny inventory again then would now be sitting on about £4,220. Good.

Valued solely within the lots of of kilos although, my holding’s value effectively beneath that. Nevertheless, I received’t complain, and I’m optimistic the share value might head larger, over time.

What’s the angle?

This small most cancers diagnostics firm specialises in liquid biopsies — non-invasive blood assessments that may detect most cancers cells or tumour DNA. These may also help docs diagnose most cancers, assess remedies, and monitor to see if the illness has returned. 

Angle’s pioneered the Parsortix liquid biopsy system. This system separates cells and captures circulating tumour cells (CTCs) from blood samples. It’s more and more being seen as a game-changing expertise within the rising area of personalised most cancers care.

There are a couple of attention-grabbing attention-grabbing issues to notice right here. Firstly, the corporate’s CTC-harvesting expertise’s patent-protected and already cleared by the FDA to be used in breast most cancers. So this de-risks the funding case with regard to the corporate’s core expertise (it really works).

In 2024, it signed two offers with AstraZeneca and one with Japanese pharma agency Eisai. That is to assist scientific trials and most cancers drug growth.

Angle can also be engaged on next-generation capabilities for an much more complete view of most cancers development. On 29 January, it introduced profitable outcomes from a brand new twin workflow, utilizing biotech firm Illumina‘s platform. Consequently, the DNA-sequencing giant has assigned its entire European Association for Cancer Research webinar on 6 February to Angle’s findings!

CEO Andrew Newland commented: “We see a substantial opportunity for both Angle and Illumina to work closely together.”

Lastly, the worldwide liquid biopsy market’s already giant and rising. Based on Fortune Enterprise Insights, it’s projected to develop from $9.63bn in 2024 to round $58bn by 2032.

Dangers galore

Now, there are additionally important dangers right here. Though it expects 2024 income to have elevated 31% yr on yr £2.9m, it’s additionally guiding for a lack of £14m (down from £20.1m in 2023).

And whereas the loss-making firm holds £12.6m in money, sufficient to final till 2026, one other share providing stays attainable. That might doubtlessly dilute shareholders like myself.

Uneven investing alternative

Nonetheless, I’m excited to see what the longer term brings as Angle pivots from promoting devices to offering providers for blue-chip pharma corporations like Astra.

Based on present forecasts, income’s anticipated to develop 49% in 2025 to £4.3m, then 68% to £7.26m in 2026. Nevertheless, if most cancers trials utilizing its expertise advance to bigger, late-stage research, income might explode.

Certainly, Angle says that touchdown a single Part 3 contract might instantly push the corporate into money flow-positive territory.

My considering right here is that I can deal with shedding a couple of hundred quid if issues flip pear-shaped. But when the agency’s expertise’s efficiently commercialised, the rewards are doubtlessly very giant for this penny inventory.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

CAPTCHA


LATEST POSTS

Security Xpress Northmead NSW Grand Opening – Blockchain Information Web site

Australia, 14th Feb 2025 – Security Xpress is happy to announce the grand opening of its latest retailer in Northmead, NSW. This enlargement marks a...

2 ETFs I feel might explode in worth in 2025!

Picture supply: Getty photographs Treasured metals proceed to seize headlines in 2025 as jitteriness...

Funding Analyst Lorenzo Riccardi Empowers World Buyers Via Axionto, Plans to Set up a New Consumer Group in Germany – Blockchain Information Web site

Famend funding analyst Lorenzo Riccardi is increasing his funding providers portfolio by Axionto, aiming to supply smarter and extra environment friendly market assist to world...

The place Meme Magic Meets Actual Wealth – Blockchain Information Web site

Dubai, UAE — The meme coin revolution is now not nearly hype—it’s about worth, safety, and actual monetary alternatives. Enter Fortunate Millionaire (LUCKY$), the next-generation...

Most Popular